Yitian Zhou

DDLS Fellow, Linköping University

Key Publications

Zhou Y, Park Y, Camara MD, Lauschke VM. Opportunities and Challenges of Population Pharmacogenomics. Ann Hum Genet. 2025.

Li K, Lauschke VM, Zhou Y. Molecular docking to investigate HLA-associated idiosyncratic drug reactions. Drug Metab Rev. 2025.

Tremmel R, Zhou Y, Camara MD, Laarif S, Eliasson E, Lauschke VM. PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes. Nucleic Acids Res. 2025.

Zhou Y, Tremmel R, Schaeffeler E, Schwab M, Lauschke VM. Challenges and opportunities associated with rare-variant pharmacogenomics. Trends Pharmacol Sci. 2022.

Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 2019.

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017.

Research Interest

Drug response varies substantially among individuals, with up to 50% of patients experiencing either a lack of therapeutic efficacy or adverse drug reactions. Our research focuses on understanding how genetic variation contributes to this variability in drug response, an interdisciplinary field known as Pharmacogenomics.

Using data-driven approaches, our research group characterizes functional pharmacogenetic variation across ethnogeographic populations to better understand the genetic basis of population-specific risks of abnormal drug responses, develops machine learning methods to interpret the functional consequences of pharmacogenetic variants, identifies clinically relevant pharmacogenomic biomarkers using biobank and clinical genotyping/sequencing data, and integrates pharmacogenetic, functional, and structural information to advance precision therapeutics and pharmacogenomics-guided drug discovery.

Through these efforts, we aim to deepen the understanding of genetic determinants of drug response and support the implementation of precision medicine in both clinical practice and drug development.

Group Members

  • Dr. Yoomi Park

Last updated: 2026-05-26

Content Responsible: Sofia Falorni(sofia.falorni@scilifelab.se)